Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody. I'm Terence Flynn, a biopharma analyst at Goldman Sachs. Today, we're very pleased to be hosting Eli Lilly. Joining us from the company is Josh Smiley, the CFO; and Mike Czapar, who's Director of Investor Relations. Thank you both for joining us today. We really appreciate the time.
Questions & Answers
Just to start at a high level, COVID-19 has obviously been front and center and is going to have near and long-term impacts on the health care system and companies' business models, if we look at delivery of care, clinical trial conduct or the supply chain. So I would be curious, Josh, to get your take on any preliminary perspectives you could share with respect to the ways which COVID might change your business model or strategy.
Sure. Thank you. Thanks, Terence. And thanks for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
